BIOMAT Database Logo BIOMAT Database Logo

Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. 2011

A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
University of Pittsburgh Cancer Institute; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine; Department of Otolaryngology. Electronic address: argirisae@upmc.edu.

BACKGROUND We studied the combination of pemetrexed, a multi-targeted antifolate, and cetuximab, an mAb against the epidermal growth factor receptor, with radiotherapy in poor prognosis head and neck cancer. METHODS Patients received pemetrexed on days 1, 22, and 43 on a dose-escalation scheme with starting level (0) 350 mg/m(2) (level -1, 200 mg/m(2); level +1, 500 mg/m(2)) with concurrent radiotherapy (2 Gy/day) and cetuximab in two separate cohorts, not previously irradiated (A) and previously irradiated (B), who received 70 and 60-66 Gy, respectively. Genetic polymorphisms of thymidylate synthase and methylenetetrahydrofolate reductase were evaluated. RESULTS Thirty-two patients were enrolled. The maximum tolerated dose of pemetrexed was 500 mg/m(2) in cohort A and 350 mg/m(2) in cohort B. Prophylactic antibiotics were required. In cohort A, two dose-limiting toxicities (DLTs) occurred (febrile neutropenia), one each at levels 0 and +1. In cohort B, two DLTs occurred at level +1 (febrile neutropenia; death from perforated duodenal ulcer and sepsis). Grade 3 mucositis was common. No association of gene polymorphisms with toxicity or efficacy was evident. CONCLUSIONS The addition of pemetrexed 500 mg/m(2) to cetuximab and radiotherapy is recommended for further study in not previously irradiated patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005971 Glutamates Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure. Glutamic Acid Derivatives,Glutamic Acids,Glutaminic Acids
D006147 Guanine

Related Publications

A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
January 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer.
April 2022, Clinical cancer research : an official journal of the American Association for Cancer Research,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.
February 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?
April 2010, The Lancet. Oncology,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications.
April 2005, Japanese journal of clinical oncology,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.
July 2013, Journal of radiation research,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
August 2016, Annals of oncology : official journal of the European Society for Medical Oncology,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
December 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.
September 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
A Argiris, and M V Karamouzis, and R Smith, and A Kotsakis, and M K Gibson, and S Y Lai, and S Kim, and B F Branstetter, and Y Shuai, and M Romkes, and L Wang, and J R Grandis, and R L Ferris, and J T Johnson, and D E Heron
Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.
December 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Copied contents to your clipboard!